Medindia LOGIN REGISTER
Medindia
Advertisement

Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals

Thursday, June 19, 2008 General News
Advertisement
NEW YORK, June 18 Danube Pharmaceuticals, Inc., aprivately held biopharmaceutical company specializing in the commercialresearch and development of innovative drugs for ophthalmology, is pleased toannounce the appointment of Dr. Barrett Katz, MD, MBA as its Chief ExecutiveOfficer.
Advertisement

"I am honored and delighted to join Danube Pharmaceuticals at thisinflection point in its history as it advances its lead programs throughclinical trials and brings novel bench research to the clinics and bedside,"said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.
Advertisement

"We are delighted to welcome Dr. Katz to our team," said David R. Guyer,MD, Chairman of Danube. "His leadership, energy and experience will transformour senior management team and complement the clinical and managerial talentswe have. His outstanding reputation in the international ophthalmologycommunity coupled with his expertise in the field of drug development, drugapproval and product launch will be invaluable for bringing Danube's productcandidates from clinical trials to market effectively and efficiently."

Dr. Katz is a renowned ophthalmologist with over 25 years of experience inclinical trials and medical strategy, drug development and regulatory issues.Prior to joining Danube, Dr. Katz served as Executive Vice President and ChiefMedical Officer of Fovea Pharmaceuticals SA, in Paris. Before that he wasVice President for Medical Affairs and Medical Strategy at EyetechPharmaceuticals, and had been integral to the team that developed Macugen(TM)and brought it to market.

Dr. Katz also served as Professor of Ophthalmology, Neurology andNeurosurgery, and as the Chairman of the Department of Ophthalmology at TheGeorge Washington University School of Medicine in Washington, D.C. Whilethere, he formulated and sponsored a joint fellowship in Ophthalmology drugdevelopment, clinical trials, and regulatory affairs with the U.S. Food andDrug Administration. Dr. Katz served on the executive committee of the OpticNeuritis Treatment Trial, and has been an active participant and principleinvestigator of many multi-centre clinical trials.

Dr. Katz currently serves as Clinical Professor of Ophthalmology at NewYork University School of Medicine as well as at the Weill Medical College ofCornell University. Dr. Katz served as a fellow at Harvard University inBoston, the National Institutes of Health, The National Hospital at Queen'sSquare in London, and the University of California at San Francisco aftercompleting residencies in Neurology at Harvard Medical School and inOphthalmology at Tufts-New England Medical Center. He received his MD withhonors from the Case Western Reserve University School of Medicine and his AB,magna cum laude, from Colgate University. He is the author of several hundredpublications, and the recipient of over two dozen major research grants.

About Danube Pharmaceuticals, Inc.

Danube is a biopharmaceutical company dedicated to the research anddevelopment of treatments for diseases of the eye. Danube's lead compoundDNB-001, is a small molecule for the treatment of glaucoma available in bothoral and topical formulation. In preclinical studies DNB-001 has been shownthrough novel mechanisms of action to both lower intraocular pressure (IOP)and to provide direct neuroprotective benefits to the optic nerve and itsretinal ganglion cells, providing a dual approach to glaucoma therapy notprovided by any currently marketed product. DNB-001 has been tested in aPhase I clinical trial in Europe and is currently being studied in a Phase IIclinical trial in Europe. For more information on Danube please visitwww.danubepharma.com .

This news release contains forward-looking statements that involve risksand uncertainties that could cause our actual results and experiences todiffer materially from anticipated results and expectations expressed in such
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close